RET Inhibitor SPP86 Is a Potential Candidate for the Clinical Treatment of Cutaneous Melanoma [Letter]
Yingjian Tan, Rui Li Department of Dermatology, Fuzhou First General Hospital, Fuzhou, People’s Republic of ChinaCorrespondence: Rui Li, Email 15773250213@163.com
Saved in:
| Main Authors: | Tan Y, Li R |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2025-02-01
|
| Series: | Drug Design, Development and Therapy |
| Subjects: | |
| Online Access: | https://www.dovepress.com/ret-inhibitor-spp86-is-a-potential-candidate-for-the-clinical-treatmen-peer-reviewed-fulltext-article-DDDT |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
RET Inhibitor SPP86 Triggers Apoptosis and Activates the DNA Damage Response Through the Suppression of Autophagy and the PI3K/AKT Signaling Pathway in Melanoma Cells
by: Zhang Y, et al.
Published: (2025-01-01) -
RET Inhibitor SPP86 is a Potential Candidate for the Clinical Treatment of Cutaneous Melanoma [Response to Letter]
by: Zhang Y, et al.
Published: (2025-03-01) -
PARP inhibitors in melanoma treatment: potential, challenges, and future directions
by: Angela Anaeme, et al.
Published: (2025-08-01) -
Application and research progress of synthetic lethality in the development of anticancer therapeutic drugs
by: Xiaoliang Gong, et al.
Published: (2024-11-01) -
Research progress on ferroptosis and PARP inhibitors in ovarian cancer: action mechanisms and resistance mechanisms
by: Jiqing Zhang, et al.
Published: (2025-04-01)